Events News

LENS Webinar #10 on ‘Drug development and drug delivery systems ‘ with Andrey Kovalevski (ORNL) & Marianna Yanez Arteta (AstraZeneca Mölndal)

LENS Webinar #10,
Global Health Threats:

Drug development & drug delivery systems

Structure of the SARS-CoV-2 main protease bound to the hepatitis C inhibitor telaprevir.
Solved by Dr. Andrey Kovalevsky’s group at ORNL. View the structure in the Protein Data Bank viewer online at

Dr. Andrey Kovalevsky
(Oak Ridge National Laboratory)
‘Targeting the Heart of a Virus: Design of SARS-CoV-2 Main Protease Inhibitors using X-rays, Neutrons and Computation’
Dr. Marianna Yanez Arteta
(AstraZeneca Mölndal)

‘Lipid Nanoparticles for mRNA delivery:
using Neutron Scattering for their successful redesign’

25 March 2021, 3:00pm CET

Chair: Zoë Fisher (ESS)

Join via Zoom:

15.00: Andrey Kovalevsky | 15.30: Marianna Yanez | 16-16.30: Discussion


Dr. Andrey Kovalevsky is a structural biologist, biochemist, and drug designer. Dr. Kovalevsky received M.Sc with Honors from Kharkov State University, Kharkov, Ukraine, and a Ph.D. from the University at Buffalo, the State University of New York. He worked at Georgia State University and the Los Alamos National Laboratory before joining the Oak Ridge National Laboratory, where he is currently a Senior R&D Scientist.

Dr. Kovalevsky’s current research focuses on studying the structure-dynamics-function relationships in macromolecular drug targets, including the design of protease inhibitors against SARS-CoV-2 and antidotes against nerve gas and pesticide poisoning, and studies of vitamin B6-dependent enzymes. His approach combines innovative biophysical and computational methodologies, such as X-ray and neutron crystallography at near-physiological conditions, vibrational spectroscopy with neutrons, biomolecular simulations, and structure-based virtual reality (VR)-assisted drug design.

Dr. Marianna Yanez Arteta is an Associate Principal Scientist at the Advanced Drug Delivery division within Pharmaceutical Sciences in AstraZeneca. In her current position she leads the development of new modalities drug products in pre-clinical and early clinical phases, including mRNA, antisense oligonucleotides and peptides. As part of her role, she has guided the development of nanomedicines for complex therapeutics from the understanding of the molecular interactions in the formulation.
Previous to this, Marianna was a postdoc researcher at AstraZeneca, where she investigated the structure of lipid nanoparticles for mRNA delivery using among other techniques neutron scattering. This work lead to a rational redesign of their composition in order to increase their efficacy. Marianna has a PhD in Physical Chemistry from Lund University, with considerable experience in the use of neutron scattering to investigate colloidal systems. She brings her expertise in scattering techniques to the screening of formulations in pre-clinical development.

Recent News & Events